Key takeaways
Semaglutide and testosterone replacement therapy (TRT) are generally considered safe to take together and may work well in combination, but only for men with clinically confirmed low testosterone.
TRT may help preserve muscle during semaglutide-related weight loss, which means more of the weight lost tends to come from fat rather than lean tissue.
Losing body fat with semaglutide may, over time, naturally raise testosterone levels, since fat tissue converts testosterone to estrogen.
This combination isn't a shortcut or “wellness stack.” It may be recommended alongside a healthy diet, regular exercise, and close medical supervision.
Here's what we'll cover
Here's what we'll cover
Here's what we'll cover
Key takeaways
Semaglutide and testosterone replacement therapy (TRT) are generally considered safe to take together and may work well in combination, but only for men with clinically confirmed low testosterone.
TRT may help preserve muscle during semaglutide-related weight loss, which means more of the weight lost tends to come from fat rather than lean tissue.
Losing body fat with semaglutide may, over time, naturally raise testosterone levels, since fat tissue converts testosterone to estrogen.
This combination isn't a shortcut or “wellness stack.” It may be recommended alongside a healthy diet, regular exercise, and close medical supervision.
More people are exploring how semaglutide and testosterone might work together to support weight loss and hormone health. But is it safe to use GLP-1 receptor agonists (such as Ozempic, Wegovy, and Mounjaro) alongside testosterone replacement therapy?
Here’s what the research says about combining semaglutide and testosterone, why some people consider it, and who is — and isn’t — a good candidate.
Can you take semaglutide and testosterone replacement therapy together?
For most people, taking semaglutide and testosterone replacement therapy (TRT) together is considered safe — there are no known direct drug interactions between the two medications. In some cases, the combination may offer additional benefits. That said, always discuss with a healthcare provider before combining semaglutide and testosterone.
Semaglutide is a GLP-1 receptor agonist that regulates blood sugar and appetite, while testosterone is a hormone that influences muscle mass, fat distribution, energy, and sex drive.
Low testosterone can also contribute to weight gain, and research suggests it is associated with excess belly fat. And, obesity can also lower testosterone levels, creating a cycle that both medications may help address.
Research suggests that weight loss can improve testosterone levels, and researchers are beginning to understand the ways GLP-1 medications may increase testosterone in men with obesity or type 2 diabetes.
Potential benefits of taking semaglutide and TRT together
Semaglutide and TRT address weight loss and hormone health differently, but in ways that can work well together. GLP-1 medications slow gastric emptying (the rate at which food moves through the digestive tract) and promote satiety; they also cross the blood-brain barrier, where they can reduce cravings and food noise. TRT has many potential benefits, including supporting muscle mass and energy levels.
Improved fat loss while maintaining muscle: While semaglutide can produce rapid weight loss, it can also lead to loss of lean muscle mass. TRT may help boost muscle protein synthesis — the process by which the body repairs muscle. One study found that men ages 65 and older with low testosterone levels who were taking TRT lost significantly less lean body mass than those on placebo, despite similar weight loss.
Better blood sugar control: Semaglutide lowers blood sugar by stimulating insulin secretion when glucose levels are elevated; TRT may reduce insulin resistance and enhance glucose uptake in muscle tissue, meaning sugar is used for energy rather than accumulating in the bloodstream.
Cardiovascular risk reduction: Both semaglutide and testosterone may support heart health. One study that looked at over 17,000 people found that people taking semaglutide had fewer serious cardiovascular events, including heart attack and stroke. TRT has been associated with lower levels of total cholesterol and LDL.
Better mood and energy levels: Low testosterone and excess weight can both affect mental health and energy levels. A clinical trial found that TRT improved mood and energy in men with hypogonadism (low testosterone). Research also suggests that GLP-1 medications may reduce the risk of worsening anxiety and depression, though any effects may be indirect.
Improves sex drive: Research on semaglutide and libido is mixed — some people report a decrease in desire, while others experience an increase, which may be tied to improvements in body image and confidence. TRT has been shown to improve libido and erectile function in people with low testosterone, and may help offset any unwanted changes in sex drive while taking semaglutide.
It's worth noting that semaglutide may boost testosterone indirectly. A 2026 systematic review found that GLP-1 receptor agonists were associated with increases in testosterone levels, particularly in people with obesity, type 2 diabetes, or functional hypogonadism. While this may improve hormonal balance in some cases, it does not necessarily replace testosterone therapy.
Potential side effects and risks of taking semaglutide and TRT together
There are no known drug interactions between semaglutide and TRT; however, each carries some potential side effects to be aware of.
Muscle loss: TRT may help preserve muscle, but appetite suppression from semaglutide can still contribute to muscle loss. Prioritizing protein and strength training while taking GLP-1 medications can help mitigate this risk.
Fertility issues: TRT is generally contraindicated for people in couples attempting to conceive, as it can significantly reduce sperm count.
Thickening of the blood: TRT stimulates red blood cell production, which can increase blood thickness. A review found that men on TRT have a significantly greater risk of developing erythrocytosis (elevation in red blood cell concentration), which could raise the risk of blood clots.
Who shouldn’t combine semaglutide and testosterone?
Semaglutide and testosterone therapy are intended for people with clinically confirmed hypogonadism (low testosterone), not as part of a weight loss “stack.” The following groups should generally not combine these medications unless specifically directed by a healthcare provider.
Men with normal testosterone levels: The American Urological Association defines healthy testosterone levels as falling between 450 and 600 ng/dL, with anything below 300 ng/dL considered low. Adding testosterone when levels are already normal can disrupt hormonal balance and potentially suppress the body's natural production.
People who are trying to conceive. Supplementing with testosterone can reduce fertility.
Men with a history of pancreatitis or thyroid cancer. Semaglutide is not recommended for those with a history of pancreatitis, medullary thyroid carcinoma (MTC), or a personal or family history of MTC or multiple endocrine neoplasia syndrome type 2 (MEN 2).
People with high hematocrit (thick blood) or clotting issues: TRT stimulates red blood cell production, which can thicken the blood and increase the risk of clotting.
People with sleep apnea. Testosterone may worsen sleep apnea by affecting airway muscle tone and reducing blood oxygen levels.
Who might consider combining semaglutide and testosterone?
The combination of semaglutide and testosterone isn't right for everyone, but for some people, it may be an effective approach to losing weight while preserving muscle mass. Consulting with a healthcare provider is recommended before combining them.
Men with obesity-related low testosterone. Low testosterone and excess body fat are closely linked — each can worsen the other. Excess fat suppresses testosterone, and low testosterone promotes weight gain. Combining semaglutide and testosterone may help address both sides of this cycle.
Men who are losing weight but not retaining muscle. Semaglutide is highly effective for fat loss, but calorie restriction can also contribute to muscle loss. TRT may help ensure that more of the weight lost comes from fat rather than lean tissue.
Men who struggle to lose weight with lifestyle changes. Low testosterone can undermine weight-loss efforts by slowing metabolism, making it harder to build muscle, and reducing energy levels. Combining semaglutide and testosterone may help curb appetite and support energy levels, making physical activity more manageable.
Men with metabolic syndrome. Metabolic syndrome — a cluster of conditions including elevated blood sugar, excess belly fat, and high blood pressure — is closely associated with low testosterone. Research suggests that TRT in men with hypogonadism may improve markers of metabolic syndrome, including blood sugar and cholesterol, which semaglutide also targets.
Bottom line
Many people wonder whether semaglutide and testosterone can be taken together. The combination isn't right for everyone, but for people with clinically low testosterone and excess weight, combining the two under medical supervision may be worth discussing with a healthcare provider.
TRT helps protect muscle during weight loss. Rapid fat loss carries a risk of losing lean muscle mass — TRT may help direct weight loss toward fat rather than lean tissue.
Losing fat may raise testosterone on its own. As semaglutide reduces body fat, less testosterone gets converted to estrogen, meaning fat loss may help restore healthier testosterone levels over time.
Healthy habits still matter. Combining testosterone and semaglutide is just one part of the equation — healthy habits like following a balanced eating plan and regular exercise will support long-term results.
Frequently asked questions (FAQs)
Can you take Ozempic and testosterone together?
Yes, it's generally considered safe to take Ozempic and testosterone together under the guidance of a healthcare provider. There are no known drug interactions between the two; however, both should only be combined under medical supervision.
Can you take testosterone and a GLP-1 at the same time?
Yes. GLP-1 medications (like semaglutide) and testosterone work through different mechanisms and are generally safe to use together.
Does semaglutide block testosterone?
No, semaglutide is not known to block testosterone. In some cases, semaglutide may actually indirectly increase testosterone levels in people with overweight or obesity, likely through its effects on weight loss.
Does testosterone help you lose belly fat?
Yes, testosterone may help with excess abdominal fat. Low testosterone and excess abdominal fat are closely linked, and TRT may help address this relationship.
Does semaglutide increase testosterone?
Semaglutide may indirectly increase testosterone levels. Fat tissue converts testosterone to estrogen, so as semaglutide reduces body fat, testosterone levels may naturally rise as a result.
Does testosterone help with weight loss?
Testosterone may help with weight loss in men with low testosterone. Restoring testosterone to normal levels can support fat burning and muscle building, which may contribute to weight loss over time.
DISCLAIMER
If you have any medical questions or concerns, please talk to your healthcare provider. The articles on Health Guide are underpinned by peer-reviewed research and information drawn from medical societies and governmental agencies. However, they are not a substitute for professional medical advice, diagnosis, or treatment.
GLP-1 Important Safety Information: Read more about serious warnings and safety info.
Ozempic Important Safety Information: Read more about serious warnings and safety info.
Wegovy Important Safety Information: Read more about serious warnings and safety info.
Mounjaro Important Safety Information: Read more about serious warnings and safety info.
References
Arillotta, D., Floresta, G., Papanti Pelletier, G. D., et al. (2024). Exploring the potential impact of GLP-1 receptor agonists on substance use, compulsive behavior, and libido: insights from social media using a mixed-methods approach. Brain Sciences, 14(6), 617. doi:10.3390/brainsci14060617. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC11202225/
Bhasin, S., Seidman, S., Travison, T. G., et al. (2024). Depressive syndromes in men with hypogonadism in the TRAVERSE trial: response to testosterone-replacement therapy. Journal of Clinical Endocrinology & Metabolism, 109(7), 1814–1826. doi: 10.1210/clinem/dgae026. Retrieved from https://academic.oup.com/jcem/article/109/7/1814/7516050
Cook, G. (2026). Quieting "food noise": how GLP-1s and mindfulness rewire the default mode network (DMN) and reward circuits. Cureus, 18(1), e100818. doi: 10.7759/cureus.100818. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12770913/
Crosnoe, L. E., Grober, E., Ohl, D., & Kim, E. D. (2013). Exogenous testosterone: a preventable cause of male infertility. Translational Andrology and Urology, 2(2), 106–113. doi: 10.3978/j.issn.2223-4683.2013.06.01. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC4708215/
Cruickshank, M., Hudson, J., Hernández, R., et al. (2024). The effects and safety of testosterone replacement therapy for men with hypogonadism: the TestES evidence synthesis and economic evaluation. Health Technology Assessment, 28(43), 1–210. doi: 10.3310/JRYT3981. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC11404359/
Deameh, M. G., Ramez, M., Rowaiee, R., et al. (2026). Effects of glucagon-like peptide-1 receptor agonists on male reproductive hormones, semen parameters, and metabolic outcomes: a systematic review. Journal of Sexual Medicine, 23(2), qdaf381. doi: 10.1093/jsxmed/qdaf381. Retrieved from https://academic.oup.com/jsm/article-lookup/doi/10.1093/jsxmed/qdaf381
Ezeamii, P. C., Adebayo, A. A., Ozojide, K. O., et al. (2025). Cardiovascular effects of testosterone replacement therapy in hypogonadal men: a systematic review of lipid profiles, inflammatory markers, and vascular function. Cureus, 17(12), e99456. doi: 10.7759/cureus.99456. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12810209/
Jones, S. D., Dukovac, T., Sangkum, P., et al. (2015). Erythrocytosis and polycythemia secondary to testosterone replacement therapy in the aging male. Sexual Medicine Reviews, 3(2), 101–112. doi: 10.1002/smrj.43. Retrieved from https://pubmed.ncbi.nlm.nih.gov/27784544/
Kelly, D. M. & Jones, T. H. (2013). Testosterone: a metabolic hormone in health and disease. Journal of Endocrinology, 217(3), R25–R45. doi: 10.1530/JOE-12-0455. Retrieved from https://joe.bioscientifica.com/view/journals/joe/217/3/R25.xml
Kim, S. D. & Cho, K. S. (2018). Obstructive sleep apnea and testosterone deficiency. World Journal of Men's Health, 37(1), 12–18. doi: 10.5534/wjmh.180017. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC6305865/
Kommu, S. & Whitfield, P. (2024). Semaglutide. StatPearls. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK603723/
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221–2232. doi: 10.1056/NEJMoa2307563. Retrieved from https://www.nejm.org/doi/10.1056/NEJMoa2307563
Mulhall, J. P., Trost, L. W., Brannigan, R. E., et al. (2018). Evaluation and management of testosterone deficiency: AUA guideline. American Urological Association. Retrieved from https://www.auanet.org/guidelines-and-quality/guidelines/testosterone-deficiency-guideline
Nassar, G. N. & Leslie, S. W. (2023). Physiology, testosterone. StatPearls. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK526128/
Neeland, I. J., Linge, J., & Birkenfeld, A. L. (2024). Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes, Obesity and Metabolism, 26(S4), 16-27. doi: 10.1111/dom.15728. Retrieved from https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.15728
Ng Tang Fui, M., Dupuis, P., & Grossmann, M. (2014). Lowered testosterone in male obesity: mechanisms, morbidity and management. Asian Journal of Andrology, 16(2), 223–231. doi: 10.4103/1008-682X.122365. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC3955331/
Okobi, O. E., Khoury, P., De la Vega, R. J., et al. (2024). Impact of weight loss on testosterone levels: a review of BMI and testosterone. Cureus, 16(12), e76139. doi: 10.7759/cureus.76139. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC11745839/
Portillo Canales, S. (2025). Anti-obesity medications can normalize testosterone levels in men. Endocrine Society. Retrieved from https://www.endocrine.org/news-and-advocacy/news-room/endo-annual-meeting/endo-2025-press-releases/portillo-canales-press-release
Rojas-Zambrano, J. G., Rojas-Zambrano, A. R., Rojas-Zambrano, A. F., et al. (2025). Benefits of testosterone hormone in the human body: a systematic review. Cureus, 17(2), e78785. doi: 10.7759/cureus.78785. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC11807418/
Saad, F., Aversa, A., Isidori, A. M., & Gooren, L. J. (2012). Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review. Current Diabetes Reviews, 8(2), 131–143. doi: 10.2174/157339912799424573. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC3296126/
Song, S. H., Sung, S., Her, Y. S., et al. (2019). Misuse of testosterone replacement therapy in men in infertile couples and its influence on infertility treatment. Clinical and Experimental Reproductive Medicine, 46(4), 173–177. doi: 10.5653/cerm.2019.00290. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC6919209/
Taipale, H., Taylor, M., Lähteenvuo, M., et al. (2026). Association between GLP-1 receptor agonist use and worsening mental illness in people with depression and anxiety in Sweden: a national cohort study. The Lancet Psychiatry, 13(4), 327–335. doi: 10.1016/S2215-0366(26)00014-3. Retrieved from https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(26)00014-3/fulltext
Travison, T. G., Araujo, A. B., Kupelian, V., et al. (2007). The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. Journal of Clinical Endocrinology & Metabolism, 92(2), 549–555. doi: 10.1210/jc.2006-1859. Retrieved from https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2006-1859
Troncoso, M. F., Pavez, M., Wilson, C., et al. (2021). Testosterone activates glucose metabolism through AMPK and androgen signaling in cardiomyocyte hypertrophy. Biological Research, 54, 3. doi: 10.1186/s40659-021-00328-4. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC7863443/
US Food and Drug Administration (FDA). (2026). Highlights of Prescribing Information: Wegovy (semaglutide) injection, for subcutaneous use; tablets, for oral use. Retrieved from https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/ee06186f-2aa3-4990-a760-757579d8f77b/spl-doc
Viola, V., Samanta, T., Nava, M. L. D., et al. (2025). Testosterone modulation of muscle transcriptomic profile during lifestyle therapy in older men with obesity and hypogonadism. Journal of Cachexia, Sarcopenia and Muscle, 16(1), e13697. doi: 10.1002/jcsm.13697. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC11924803/
Yassin, D. J., Doros, G., Hammerer, P. G., & Yassin, A. A. (2014). Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life. Journal of Sexual Medicine, 11(6), 1567–1576. doi: 10.1111/jsm.12523. Retrieved from https://pubmed.ncbi.nlm.nih.gov/24712761/














